The results highlight the heterogeneity of type 2 diabetes and may help explain the differences in disease progression and response to glucose-lowering treatment seen in clinical practice, an accompanying comment
Adults who were expected to have an ICU stay of at least three days and who had persistent hyperglycemia for up to six hours after admission, were receiving insulin, or both had a peripheral venous catheter placed and connected to a continuous
Researchers conducted an online survey of an international social media group of people with type 1 diabetes who follow a very low-carb diet (up to 30 g/d derived from fibrous vegetables and nuts).
Clinicians should be aware of the strengths and weaknesses of diabetes apps and be able to advise patients on their use, according to the European Association for the Study of Diabetes and the American Diabetes Association.
The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.
Patients with diabetes who were taking any beta-blocker, a beta-1 selective beta-blocker, or a specific beta-blocker had significantly higher risk for all-cause mortality versus patients with diabetes who were not taking a beta-blocker.
The retrospective study at a single tertiary care referral medical center compared cost-effectiveness of care from a specialized diabetes team with care from a primary service team.
While the proportion of U.S. adults with diabetes who attained glycemic, blood pressure, and lipid control increased during the study period, there was a lack of progress related to dietary guidelines.
Between 2007 and 2014, more Medicare beneficiaries were newly prescribed metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, while fewer received long-acting sulfonylureas or thiazolidinediones.
After four years of follow-up, patients who had received intensive treatment during the trial had similar systolic blood pressure (BP) to those who had been on standard treatment but lower rates of cardiovascular (CV) events.